Manufacturer
Pfizer Italia S.r.l.
Contents
Exemestane
Indication
Adjuvant treatment of post-menopausal women w/ estrogen receptor +ve early breast cancer who have received 2-3 yr tamoxifen & switched to Aromasin for completion of a total of 5 consecutive yr adjuvant hormonal therapy. Advanced breast cancer in women w/ natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy alone. Postmenopausal woman whose disease has progressed following multiple hormonal therapies.
Instruction
Should be taken with food.
Drug interaction
In vitro evidence showed that the drug is metabolized through cytochrome P450 (CYP) 3A4 and aldoketoreductases and does not inhibit any of the major CYP isoenzymes. In a clinical pharmacokinetic study, the specific inhibition of CYP3A4 by ketoconazole showed no significant effects on the pharmacokinetics of exemestane.Although pharmacokinetic effects were observed in a pharmacokinetic interaction study with rifampicin, a potent CYP3A4 inducer, the pharmacologic activity (i.e., estrogen suppression) was not affected, and a dosage adjustment is not required.
Malaysia
